Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.41 |
| ▸ | CBFB | Q13951 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1145924 | 0.79 | HRH3 (0.50) | ALDH1A1MAPTHPGDHTTGAA | |
| SCHEMBL9133922 | 0.78 | MAPT (0.60) | APPALDH1A1TP53MAPTHPGD | |
| SCHEMBL6740529 | 0.78 | ALDH1A1 (0.41) | ALDH1A1CYP3A4TDP1MAPTHPGD | |
| SCHEMBL6740524 | 0.78 | ALDH1A1 (0.41) | ALDH1A1MAPTHPGDHTTGAA | |
| SCHEMBL2204601 | 0.77 | ALDH1A1 (0.44) | ALDH1A1MAPTHPGDHTTGAA | |
| SCHEMBL22335464 | 0.76 | MAPT (0.43) | ALDH1A1TP53CYP3A4MAPTHPGD | |
| SCHEMBL14921415 | 0.75 | CA2 (0.52) | TDP1 | |
| SCHEMBL6721322 | 0.74 | ALDH1A1 (0.41) | ALDH1A1MAPTHPGDHTTGAA | |
| SCHEMBL10163319 | 0.74 | METAP2 (0.41) | ALDH1A1TP53MAPTHPGDHTT | |
| SCHEMBL10577638 | 0.74 | KIF11 (0.44) | ALDH1A1TP53TDP1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182050-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | claimed |
| US-6812225-B2 | PYSCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | ASTRAZENECA AB (SE) | 2004-11-02 | — | — | US | claimed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-9045423-B2 | Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient | KOWA COMPANY, LTD. (JP) | 2015-06-02 | — | — | US | disclosed |
| US-20140249144-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | KOWA COMPANY, LTD. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-8791090-B2 | Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient | KOWA COMPANY, LTD. (JP) | 2014-07-29 | — | — | US | disclosed |
| EP-2415764-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | Kowa Company, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120004197-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | KOWA COMPANY, LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| EP-1353915-A2 | THERAPEUTIC CHROMAN COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1353913-A2 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| WO-2002055012-A2 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055013-A2 | THERAPEUTIC CHROMONE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055014-A2 | THERAPEUTIC CHROMAN COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| US-5387657-A | Liquid crystal polymers; high glass transition temperatures; enhanced unidirectional mechanical properties; coatings, castings, encapsulation, lamination, composites, molding materials | THE DOW CHEMICAL COMPANY (US) | 1995-02-07 | — | — | US | disclosed |
| WO-1994025501-A1 | EPOXY RESINS CONTAINING THIADIAZOLE AND/OR OXADIAZOLE MOIETIES | THE DOW CHEMICAL COMPANY (US) | 1994-11-10 | — | — | WO | disclosed |
| US-5290887-A | Liquid crystal polymers for coatings, castings, encapsulation, electronics or laminates | THE DOW CHEMICAL COMPANY (US) | 1994-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | HTR1A, HTR1B, HTR1D | APP 722/4885ALDH1A1 592/4885TP53 4870/4885 |
| US-20140249144-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | EPOR, HBG1, HBG2 | APP 4542/4885ALDH1A1 1491/4885TP53 3376/4885 |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | HTR1B, HTR1D, HTR1A | APP 730/4885ALDH1A1 517/4885TP53 4877/4885 |
| US-20120004197-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | EPOR, HBG1, HBG2 | APP 4542/4885ALDH1A1 1491/4885TP53 3376/4885 |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | APP 755/4885ALDH1A1 399/4885TP53 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.